Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials
Cornelia Eckert, Catriona Parker, Anthony V. Moorman, Julie Irving, Renate Kirschner‐Schwabe, Stefanie Groeneveld‐Krentz, Tamás Révész, Peter M. Hoogerbrugge, Jeremy Hancock, Rosemary Sutton, Guenter Henze, Christiane Chen‐Santel, Andishe Attarbaschi, Jean‐Pierre Bourquin, Lucie Šrámková, Martin Zimmermann, Shekhar Krishnan, Arend von Stackelberg, Vaskar Saha
Abstract
AIM: Outcomes of children with high-risk (HR) relapsed acute lymphoblastic leukaemia (ALL) (N = 393), recruited to ALLR3 and ALL-REZ BFM 2002 trials, were analysed. Minimal residual disease (MRD) was assessed after induction and at predetermined time points until haematopoietic stem cell transplantation (SCT). METHODS: Genetic analyses included karyotype, copy-number alterations and mutation analyses. Ten-year survivals were analysed using Kaplan-Meier and Cox models for multivariable analyses. RESULTS: ), HR cytogenetics and TP53 alterations in BCP-ALL. CONCLUSION: Improvements in outcomes for HR ALL relapses require novel compounds in induction therapy to improve remission rates and immune targeted therapy after induction to maintain remission after SCT. TRIAL REGISTRATION: ALLR3: NCT00967057; ALL REZ-BFM 2002: NCT00114348.